PRCL Research Inc.
1255 University, # 1610
Montreal Quebec H3B 3X3
PRCL Research Inc., based in Montreal, Quebec, is a special purpose company created to develop one compound to proof-of-concept. The project is fully financed by TVM Life Science Ventures VII and Fonds de solidarité FTQ (the “Fonds”). To date, the biopharmaceutical assetshave completed pilot tox studies with the goal of selecting one compound to begin GLP tox studies and file an Investigational New Drug (IND) application in 2015.
If the IND is approved, the PRCL compound will be tested in single ascending dose study in healthy male volunteers and, if appropriate, in a multiple ascending dose study eventually leading to a clinical proof of concept (POC) in moderate to severe psoriasis patients. PRCL Research Inc. is funded by TVM Life Science Ventures VII and the Fonds, and is led by an experienced management team.